Benjamin Halladay insider trades

Open-market stock purchases and sales by Benjamin Halladay, Chief Financial Officer at Achieve Life Sciences, Inc, from SEC Form 4 filings since Dec 9, 2022.

Recent trades

DateStockTradeValue
Oct 5, 2026ACHV Achieve Life Sciences, IncBought (not open market)—
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)—
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)$410K
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)$320K
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)$540K
Jun 17, 2026ESPR Esperion Therapeutics, IncSold$34K
Mar 17, 2026ESPR Esperion Therapeutics, IncSold$17.4K
Mar 13, 2026ESPR Esperion Therapeutics, IncBought (not open market)—
Mar 13, 2026ESPR Esperion Therapeutics, IncBought (not open market)—
Dec 17, 2025ESPR Esperion Therapeutics, IncSold$26.9K

Companies traded

  • ACHV Achieve Life Sciences, Inc: other filings, last Oct 5, 2026
  • ESPR Esperion Therapeutics, Inc: 11 sales, last Jul 13, 2026

Get free alerts when Benjamin Halladay files a new trade →